Bailey 2013 (2626 Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.) |
546 |
24 |
53.48 |
59.9 |
NR |
8.05 |
85.91 |
Metformin |
Dapagliflozin 2.5 mg Dapagliflozin 5 mg Dapagliflozin 10 mg |
Wilding 2012 (2525 Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405-15.) |
808 |
48 |
47.28 |
59.3 |
13.6 |
8.53 |
93.82 |
Insulin and/or OAD |
Dapagliflozin 2.5 mg Dapagliflozin 5 mg Dapagliflozin 10 mg |
Wilding 2009 (2727 Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-62.) |
71 |
12 |
59.15 |
56.7 |
12.3 |
8.43 |
102.10 |
Insulin |
Dapagliflozin 10 mg Dapagliflozin 20 mg |
Rosenstock 2012 (2828 Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-8.) |
420 |
48 |
49.52 |
53.4 |
NR |
8.37 |
86.30 |
Pioglitazone |
Dapagliflozin 5 mg Dapagliflozin 10 mg |
Bode 2013 (2929 Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41(2):72-84.) |
714 |
102 |
55.46 |
52.9 |
11.7 |
7.70 |
89.50 |
Naïve or OAD |
Canagliflozin 100 mg Canagliflozin 300 mg |
Wilding 2013 (3030 Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267-82.) |
343 |
12 |
51.02 |
57.4 |
5.9 |
7.76 |
89.76 |
Metformin |
Canagliflozin 100 mg Canagliflozin 300 mg |
Zinman 2015 (88 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373(22):2117-28.) |
7020 |
192 |
71.45 |
63.1 |
NR |
8.07 |
86.3 |
Any |
Empagliflozin 10 mg Empagliflozin 25 mg |
Yang 2018 (3131 Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH, et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial. J Diabetes. 2018;10:589-99.) |
275 |
24 |
47.8 |
57.5 |
12.5 |
8.55 |
71.8 |
Insulin ± OAD |
Dapagliflozin 10 mg |
Januzzi 2017 (3232 Januzzi JL Jr, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70:704-12.) |
714 |
26 |
55.4 |
63.6 |
NR |
NR |
NR |
OAD |
Canagliflozin 100 mg Canagliflozin 300 mg |
Haering 2015 (3333 Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110:82-90.) |
666 |
76 |
50.9 |
57.1 |
NR |
8.1 |
76.9 |
Metformin + sulphonylurea |
Empagliflozin 10 mg Empagliflozin 25 mg |
Jabbour 2014 (3434 Jabbour SA, Hardy E, Sugg J, Parikh S; Study 10 Group. Dapagliflozin Is Effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740-50.) |
447 |
24 |
54.80 |
54.8 |
5.67 |
7.95 |
90.1 |
Sitagliptin ± metformin |
Dapagliflozin 10 mg |
Matthaei 2015 (3535 Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E; Study 05 Group. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab. 2015;17:1075-84.) |
216 |
24 |
49.07 |
61 |
9.4 |
8.16 |
89.35 |
Metformin + sulphnylurea |
Dapagliflozin 10 mg |
Leiter 2014 (3636 Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62:1252-62.) |
964 |
24 |
67.01 |
63.7 |
NR |
8.0 |
93.8 |
OAD |
Dapagliflozin 10 mg |
Stenlöf 2013 (3737 Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-82.) |
584 |
26 |
44.18 |
55.4 |
4.3 |
8.00 |
86.8 |
Diet + exercise |
Canagliflozin 100 mg Canagliflozin 300 mg |
Roden 2013 (3838 Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208-19.) |
899 |
24 |
61 |
55 |
NR |
7.88 |
78.4 |
No treatment for at least 12 weeks |
Empagliflozin 10 mg Empagliflozin 25 mg |
Tikkanen 2015 (3939 Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420-8.) |
823 |
12 |
60.1 |
60.2 |
NR |
7.90 |
NR |
Diet + exercise |
Empagliflozin 10 mg Empagliflozin 25 mg |
Yale 2014 (4040 Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016-27.) |
269 |
52 |
60.59 |
68.5 |
16.3 |
8.00 |
NR |
Insulin |
Canagliflozin 100 mg Canagliflozin 300 mg |
Fulcher 2016 (4141 Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:82-91.) |
316 |
18 |
65.50 |
63.0 |
12.6 |
8.1 |
NR |
DPP-4 inhibitor |
Canagliflozin 100 mg Canagliflozin 300 mg |